Novo Nordisk's corporate structure has a few quirks that investors need to know about.
WILMINGTON, Del., December 11, 2023--Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III trial showed danicopan as add-on to standard of care C5 inhibitor therapy ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) continued to demonstrate clinical benefit for patients with paroxysmal nocturnal hemoglobinuria (PNH) who experience clinically significant extravascular hemolysis (EVH).1
It's hard to see a presentation or read a press release by a major pharmaceutical company these days without hearing about how they're planning to use artificial intelligence (AI) to supercharge their drug development efforts -- and AstraZeneca's (NASDAQ: AZN) materials are no different. Let's probe this issue by looking at the collaboration and acquisition activity that the company is pursuing. It's no surprise that drugmakers are interested in using AI to accelerate the pace of drug development.